Larimar Therapeutics News

Larimar Therapeutics | 10-Q: Q3 2024 Earnings Report

Oct 31 05:07

Larimar Therapeutics | 8-K: Larimar Therapeutics Reports Third Quarter 2024 Operating and Financial Results

Oct 30 19:07

Larimar Therapeutics | 10-Q: Q2 2024 Earnings Report

Aug 9 02:44

Larimar Therapeutics | 8-K: Larimar Therapeutics Reports Second Quarter 2024 Operating and Financial Results

Aug 7 19:06

Larimar Therapeutics | 10-Q: Q1 2024 Earnings Report

May 10 04:22

Larimar Therapeutics | 8-K: Larimar Therapeutics Reports First Quarter 2024 Operating and Financial Results

May 9 19:07

Larimar Therapeutics | 10-K: FY2023 Annual Report

Mar 15 04:30

Larimar Therapeutics | 8-K: Larimar Therapeutics Reports Fourth Quarter and Full Year 2023 Operating and Financial Results and Provides Update on Nomlabofusp Development

Mar 15 04:10

Larimar Therapeutics | 10-Q: Q3 2023 Earnings Report

Nov 15, 2023 02:51

Larimar Therapeutics | 8-K: Larimar Therapeutics Reports Third Quarter 2023 Operating and Financial Results

Nov 14, 2023 20:14

Larimar Therapeutics | 10-Q: Q2 2023 Earnings Report

Aug 11, 2023 04:05

Larimar Therapeutics | 8-K: Larimar Therapeutics Reports Second Quarter 2023 Operating and Financial Results

Aug 10, 2023 19:03

Larimar Therapeutics | 10-Q: Q1 2023 Earnings Report

May 16, 2023 04:03

Larimar Therapeutics | 8-K: Larimar Therapeutics Reports Preliminary Top-line Data from Phase 2 Trial's 25 mg Cohort Showing Increases in Frataxin Levels in Patients with Friedreich's Ataxia and First Quarter 2023 Financial Results

May 15, 2023 19:05

Larimar Therapeutics | 10-K: FY2022 Annual Report

Mar 15, 2023 04:03

Larimar Therapeutics | 8-K: Larimar Therapeutics Reports Fourth Quarter and Full Year 2022 Operating and Financial Results

Mar 14, 2023 19:32

Larimar Therapeutics | 10-Q: Q3 2022 Earnings Report

Nov 10, 2022 22:20

Larimar Therapeutics | 8-K: Larimar Therapeutics Reports Third Quarter 2022 Operating and Financial Results

Nov 10, 2022 20:01

Larimar Therapeutics | 10-Q: Q2 2022 Earnings Report

Aug 12, 2022 04:32

Larimar Therapeutics | 8-K: Larimar Therapeutics Provides Updates on CTI-1601 Clinical Program Following a Type C Meeting with the U.S. Food and Drug Administration and Reports Second Quarter 2022 Operating and Financial Results

Aug 12, 2022 04:13